Merit Medical Buys View Point Medical for About $140 Million, Adding OneMark Tumor Markers

Merit Medical Systems said on Wednesday, April 1, that it has acquired View Point Medical, a Carlsbad, California, company that makes the OneMark Detection Imaging System and OneMark Tissue Markers, used to locate breast and soft tissue tumors. View Point is now a wholly owned subsidiary of Merit, according to Merit's press release, filed with the SEC.

The aggregate consideration, including the assumption of View Point liabilities, is about $140 million. Merit paid $90 million in cash at closing and will make two deferred payments of $25 million each, due no later than the first and second anniversaries of the closing.

The product

The OneMark system consists of a surgical detection console and ultrasound-enhanced tissue markers and is cleared by the Food and Drug Administration for its intended use, Merit said. Physicians place the markers during biopsies and visualize them using ultrasound, MedTech Dive reported.

Merit already sells a localization product, its SCOUT platform, which uses radar. Merit said using the two together gives physicians more options to mark a suspicious area during the initial biopsy, which it said may reduce the need for a separate procedure to mark the tumor before surgery. The company estimated that lesions which could be localized at the time of biopsy represent about 1.3 million procedures a year in the United States.

"Merit has built a market leadership position in wire-free, non-radioactive breast localization procedures," chief executive Martha Aronson said.

Analysts at Needham said in a note that they believe it would be rare for physicians to use OneMark and SCOUT in the same patient, and that OneMark may be preferred where ultrasound systems are readily available, MedTech Dive reported. The analysts called the deal consistent with Merit's focus on tuck-in acquisitions of complementary products.

Financial outlook

Merit projects the acquisition will contribute $2 million to $4 million in revenue from April 1 through December 31, 2026, and reduce its previously forecast non-GAAP earnings per share by about $0.05 this year. For 2027, it projects revenue of $14 million to $16 million and an addition to non-GAAP earnings per share. Merit said it expects OneMark sales to grow at least 20% a year with 70% non-GAAP gross margins.

The deal extends a run of acquisitions by Merit. In 2024 it agreed to buy EndoGastric Solutions for $105 million and Cook Medical's lead management portfolio for about $210 million, and last year it paid $120 million for Biolife, according to MedTech Dive.

Merit said it would discuss the acquisition on its first-quarter investor call on April 30.